<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772744</url>
  </required_header>
  <id_info>
    <org_study_id>2667-20-3-2016</org_study_id>
    <nct_id>NCT02772744</nct_id>
  </id_info>
  <brief_title>Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4</brief_title>
  <official_title>Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, cohort study in Faculty of Medicine, Zagazig University, Egypt. From
      June to December, 2016, investigators will follow up patients with chronic Hepatitis C virus
      genotype 4 receiving daclatasvir-sofosbuvir treatment regimen within the national program of
      Egyptian ministry of health and population. The primary outcomes are safety of the treatment
      and the sustained virologic response 12 weeks after discontinuation of therapy. For the
      secondary outcomes, investigators will measure the change in health related quality of life
      and investigate the genetic sequence of viral RNA of resistant patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy measured by Sustained Virologic Response Rate</measure>
    <time_frame>12 weeks posttreatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3/4 adverse events [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Neutropenia [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
    <description>Neutropenia: Grade 3, 500-749/mm3; Grade 4, &lt;500/mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Lymphopenia [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
    <description>Lymphopenia: Grade 3, 350-499/mm3; Grade 4, &lt;350/mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anaemia [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
    <description>Anaemia: Grade 3, haemoglobin 7.0-8.9 g/dL; Grade 4, &lt;7.0 g/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Thrombocytopenia [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
    <description>Thrombocytopenia: Grade 3, 25 000-49 999/mm3; Grade 4, &lt;25 000/mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of (Increased total Bilirubin) [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
    <description>Bilirubin elevations: Grade 3, 2.6-5×ULN; Grade 4, &gt;5×ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of elevated Alanine Aminotransferase [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
    <description>Alanine Aminotransferase elevations: Grade 3, 5.1-10×upper limit of normal (ULN); Grade 4, &gt;10×ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Fatigue [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Headache [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Pruritus [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Insomnia [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Rash [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Nausea [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Myalgia [Safety]</measure>
    <time_frame>Within the treatment period (12 or 24 weeks according to the treatment regimen)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQoL)</measure>
    <time_frame>24 weeks</time_frame>
    <description>HRQoL will be assessed using the Arabic version of SF-36 questionnaire (SF-36™ Health Survey)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1: Easy to treat group</arm_group_label>
    <description>Treatment naïve
Total serum bilirubin ≤ 1.2 mg/dl
Serum albumin ≥ 3.5 g/dl
International normalized ratio ≤ 1.2
Platelet count ≥ 150000 mm3
This group will be receiving Sofosbuvir + daclatasvir for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Difficult to treat group</arm_group_label>
    <description>Peg interferon treatment experienced.
Total serum bilirubin ≥ 1.2 mg/dl
Serum albumin ≤ 3.5 g/dl
International normalized ratio ≥ 1.2
Platelet count ≤ 150000 mm3
This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Sofosbuvir resistant cases</arm_group_label>
    <description>This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir 60 MG Oral Tablet [Daklinza]</intervention_name>
    <description>Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein</description>
    <arm_group_label>Group 1: Easy to treat group</arm_group_label>
    <arm_group_label>Group 2: Difficult to treat group</arm_group_label>
    <arm_group_label>Group 3: Sofosbuvir resistant cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400 MG Oral Tablet [Sovaldi]</intervention_name>
    <description>Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor</description>
    <arm_group_label>Group 1: Easy to treat group</arm_group_label>
    <arm_group_label>Group 2: Difficult to treat group</arm_group_label>
    <arm_group_label>Group 3: Sofosbuvir resistant cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin Oral Product</intervention_name>
    <description>Ribavirin (twice-daily) dosed according to body weight (&lt;75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)</description>
    <arm_group_label>Group 2: Difficult to treat group</arm_group_label>
    <arm_group_label>Group 3: Sofosbuvir resistant cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include male or female patients ≥ 18 years, HCV RNA≥ 104 IU/mL, HCV
        genotype 4, screening ECG without clinically significant abnormalities.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HCV genotype 4

          -  Age ≥ 18 years

          -  HCV RNA≥ 104 IU/mL

          -  Screening ECG without clinically significant abnormalities.

        Exclusion Criteria:

          -  Total serum bilirubin &gt; 3 mg/dl.

          -  Serum albumin &lt; 2.8 g/dl.

          -  INR ≥ 1.7

          -  Platelet count &lt; 50000/mm3.

          -  Hepatic cell carcinoma except four weeks after intervention aiming to cure with no
             evidence of activity by dynamic imaging (CT or MRI).

          -  Extra hepatic malignancy except after two years of disease free interval

          -  Pregnancy or inability to use contraception.

          -  Inadequately controlled diabetes mellitus (HbA1c &gt; 9%).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samah A Loutfy</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Institute, Cairo University, Cairo, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Negida</last_name>
    <phone>+201125549087</phone>
    <email>ahmed01251@medicine.zu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hussien Ahmed, MD</last_name>
    <phone>+201006037334</phone>
    <email>hoseen011232@medicine.zu.edu.eg</email>
  </overall_contact_backup>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843Orig1s000lbl.pdf</url>
  </link>
  <reference>
    <citation>Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S; HALLMARK-QUAD Study Team. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul;63(1):30-7. doi: 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19.</citation>
    <PMID>25703086</PMID>
  </reference>
  <reference>
    <citation>Hézode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M; COMMAND-4 study team. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015 Aug 27;21(3):195-205. doi: 10.3851/IMP2985. [Epub ahead of print]</citation>
    <PMID>26313445</PMID>
  </reference>
  <reference>
    <citation>Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC Jr, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P; ALLY-2 Investigators. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20;373(8):714-25. doi: 10.1056/NEJMoa1503153. Epub 2015 Jul 21.</citation>
    <PMID>26196502</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>October 8, 2017</last_update_submitted>
  <last_update_submitted_qc>October 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Ahmed Negida</investigator_full_name>
    <investigator_title>Mr.</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C virus genotype 4</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Virologic Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

